Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Brain somatostatin concentrations do not decrease in progressive supranuclear palsy.

J Epelbaum1, F Javoy-Agid, E Hirsch

  • 1Laboratoire de Médecine Expérimentale U. 159, INSERM, Paris, France.

Journal of Neurology, Neurosurgery, and Psychiatry
|November 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

6-hydroxydopamine lesions of the locus coeruleus induce a paradoxical increase in growth hormone secretion in male rats.

Journal of neuroendocrinology·2011
Same author

Correct use of impact factors.

Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences·2010
Same author

(Hydroxyproline(9)) luteinizing hormone-releasing hormone: A novel peptide in mammalian and frog hypothalamus.

Neurochemistry international·2010
Same author

Neural mechanisms involved in pituitary control.

Neurochemistry international·2010
Same author

PKC modulation of inhibitory coupling of angiotensin II receptors with adenylate cyclase in lactotroph cells.

Molecular and cellular neurosciences·2009
Same author

Coculture of rat melanotrophs with hypothalamic cells enhances differentiation of dopaminergic neurons.

Molecular and cellular neurosciences·2009

Progressive supranuclear palsy (PSP) shows reduced choline acetyl transferase (CAT) in specific brain areas, unlike Alzheimer's or Parkinson's disease. Somatostatin levels remained unchanged in PSP patients compared to controls.

Area of Science:

  • Neuroscience
  • Neuropathology
  • Neurochemistry

Background:

  • Progressive Supranuclear Palsy (PSP) is a neurodegenerative disease with distinct clinical features.
  • Understanding the neurochemical underpinnings of PSP is crucial for differential diagnosis and potential therapeutic targets.
  • Previous research suggests neurotransmitter deficits in other neurodegenerative diseases like Alzheimer's and Parkinson's.

Purpose of the Study:

  • To investigate the concentrations of somatostatin and choline acetyl transferase (CAT) in the brains of PSP patients.
  • To compare these neurochemical levels with those in age-matched healthy controls.
  • To determine if PSP-associated intellectual deterioration correlates with specific neurotransmitter deficits.

Main Methods:

  • Measurement of somatostatin concentrations and CAT activity in post-mortem brain tissue.

Related Experiment Videos

  • Comparison between nine PSP brains and 19 matched control brains.
  • Analysis across multiple brain regions, including neocortical, limbic, and subcortical areas.

    • Main Results:

    • Choline acetyl transferase (CAT) activity was significantly reduced in the caudate nucleus and limbic areas (amygdala, hippocampus, cingulate cortex) of PSP brains.
    • CAT activity in neocortical areas (frontal, temporal) did not differ between PSP patients and controls.
    • Somatostatin concentrations were comparable between PSP patients and controls across all examined brain regions.

    Conclusions:

    • Intellectual deterioration in PSP is not associated with deficits in neocortical somatostatin or CAT levels.
    • The observed regional reduction in CAT activity in PSP differentiates it from the broader deficits seen in Alzheimer's and Parkinson's disease.
    • These findings highlight specific neurochemical alterations in PSP, potentially aiding in its distinction from other neurodegenerative conditions.